Healthcare Resource Use and Burden Associated with Influenza Transmission Among Household Members with a Primary Infection: Commercial Claims Data Analysis.
children
claims
household
influenza
observational
retrospective
Journal
ClinicoEconomics and outcomes research : CEOR
ISSN: 1178-6981
Titre abrégé: Clinicoecon Outcomes Res
Pays: New Zealand
ID NLM: 101560564
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
01
2021
accepted:
13
04
2021
entrez:
7
5
2021
pubmed:
8
5
2021
medline:
8
5
2021
Statut:
epublish
Résumé
To assess the burden of influenza transmission and care-seeking patterns over 3 influenza seasons among commercially insured households with a primary influenza infection. This retrospective cohort study used commercial claims data from the US MarketScan Among 1,224,808 households with ≥2 members and a primary case of influenza, a secondary case of influenza was reported in 119,883 households (9.8%). A secondary diagnosed case of influenza occurred within 4 days of the primary diagnosis in 93,883 (78.3%) of those households. Both primary and secondary diagnosed influenza cases occurred most often among children (~60%). Household size was positively correlated to both the risk of a second case (6.4% of households with 2 or 3 members versus 12.6% of households with ≥4 members, Claims data for 3 influenza seasons (2014, 2015, 2016) showed that intrahousehold transmission of influenza occurs in approximately 10% of households with a primary case and poses a higher burden on larger households. Intrahousehold transmission of influenza represents a large healthcare resource use burden, with an unmet need for interventions that limit transmission.
Identifiants
pubmed: 33958880
doi: 10.2147/CEOR.S298992
pii: 298992
pmc: PMC8096342
doi:
Types de publication
Journal Article
Langues
eng
Pagination
335-342Informations de copyright
© 2021 Wallick et al.
Déclaration de conflit d'intérêts
All authors are full-time employees of Genentech, Inc. and hold Genentech stock.
Références
J Infect Chemother. 2013 Aug;19(4):740-9
pubmed: 23732307
Br J Gen Pract. 2004 Sep;54(506):684-9
pubmed: 15353055
Am J Public Health. 1993 Dec;83(12):1712-6
pubmed: 8259800
Epidemiol Infect. 2017 Mar;145(4):723-727
pubmed: 27916020
PLoS Comput Biol. 2010 Jan 29;6(1):e1000656
pubmed: 20126529
PLoS One. 2012;7(2):e31519
pubmed: 22359599
N Engl J Med. 2020 Jul 23;383(4):309-320
pubmed: 32640124
CMAJ Open. 2016 Aug 22;4(3):E463-E470
pubmed: 27730110
Trends Microbiol. 2016 Feb;24(2):123-133
pubmed: 26612500
Am J Epidemiol. 2008 Apr 1;167(7):775-85
pubmed: 18230677
Am J Prev Med. 2015 Apr;48(4):384-91
pubmed: 25700653
J Infect Dis. 2010 Apr 1;201(7):984-92
pubmed: 20187740
Hum Vaccin Immunother. 2017 Sep 2;13(9):2041-2047
pubmed: 28700268
Lancet Infect Dis. 2015 Jun;15(6):654-62
pubmed: 25788164
Hong Kong Med J. 2013 Jun;19 Suppl 4:19-23
pubmed: 23775182
N Engl J Med. 2010 Jun 10;362(23):2175-2184
pubmed: 20558368
PLoS Pathog. 2014 Aug 21;10(8):e1004310
pubmed: 25144780
Emerg Infect Dis. 2011 Jun;17(6):990-9
pubmed: 21749759
Epidemiology. 2012 Jul;23(4):531-42
pubmed: 22561117
N Engl J Med. 2009 Dec 31;361(27):2619-27
pubmed: 20042753
Clin Infect Dis. 2017 Mar 15;64(6):736-742
pubmed: 28011603
J Infect. 2014 Jun;68(6):581-90
pubmed: 24491598
Clin Infect Dis. 2010 Mar 1;50(5):707-14
pubmed: 20121573